Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of
Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense
oligonucleotide (ASO), in combination with docetaxel can prolong survival time compared to
docetaxel alone in participants with locally advanced or metastatic urothelial carcinoma (UC)
that are relapsed or refractory after receiving a platinum-containing regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Noah Hahn, M.D.
Collaborators:
Achieve Life Sciences Hoosier Cancer Research Network OncoGenex Technologies